{
  "docId": "019de074-3cc2-7451-b551-f16094d96b35",
  "docSlug": "3309edf11a92b656dd98b92129b54a19",
  "documentTitle": "Recursion Pharmaceuticals | Investor Day Presentation Deck | 143 slides",
  "authorId": "recursion-pharmaceuticals",
  "authorName": "Recursion Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 82,
  "pageCount": 120,
  "prevPage": 81,
  "nextPage": 83,
  "slideType": "roadmap",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The chart uses a horizontal bar format to represent the stage of development for various oncology and rare disease programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-3cc2-7451-b551-f16094d96b35/82",
  "deckHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35",
  "deckJsonHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35.json",
  "deckAnchorHref": "/decks/019de074-3cc2-7451-b551-f16094d96b35#slide-82",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.54,
        "x": 0.418,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Horizontal bars representing development stages for oncology and rare disease programs.",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa48278f-c52d-485e-a81a-c1c7b2dc7b05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.038,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain and UK. (1) Our program has the potential to address a number of indications driven by MYC alterations, totalling 54,000 patients in the US and EU5 annually. We have not finalized a target product profile for a specific indication. (2) Our program has the potential to address a number of indications in this space. (3) Prevalence for hereditary and sporadic symptomatic population. (4) Annual US and EU5 incidence for all NF2-driven meningiomas.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04edef39-32ce-4266-a39c-07e35deffc45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.038,
        "y": 0.84
      },
      "kind": "paragraph",
      "text": "More than a dozen early discovery and research programs in oncology, neuroscience, inflammation & immunology, and rare disease",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65c57fb7-7f83-4e06-84b1-8904e1db8412",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.038,
        "y": 0.15
      },
      "kind": "table",
      "text": "Pipeline table with columns for Therapeutic Area, Indication, and development stages (Late Discovery, Preclinical, Phase 1, Phase 2, Phase 3).",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3ad9590-cb35-41db-80b6-f8939b170c00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.038,
        "y": 0.045
      },
      "kind": "title",
      "text": "Our pipeline reflects the scale and breadth of our approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "907224bb-550f-4382-8b98-ac026feb37bb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 15,
      "beatId": "136386a5-6141-40a4-88e2-1f9e9bd0026c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 120,
      "from": 15,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "781e998b-dc37-46ea-ab12-3271a3953fda",
      "evidence": "The document presents Recursion's solution, including its technology, approach, and progress in drug discovery.",
      "position": 1,
      "objective": "How can Recursion's technology and approach improve drug discovery outcomes?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}